CT-155, a smartphone app, integrates psychosocial interventions using an adaptive goal-setting technique.
A phase 3 trial has shown that it reduces negative symptoms of schizophrenia, with data presented at the 38th Annual European College of Neuropsychopharmacology Congress.
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapy CT-155 reduces schizophrenia symptoms.